[Federal Register: April 22, 2008 (Volume 73, Number 78)]
[Notices]
[Page 21679-21681]
[DOCID:fr22ap08-86]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-57671; File No. SR-NYSE-2008-27]

Self-Regulatory Organizations: New York Stock Exchange LLC;
Notice of Filing and Order Granting Accelerated Approval of Proposed
Rule Change Amending NYSE Rule Interpretation 344/02 (Research Analysts
and Supervisory Analysts)

April 16, 2008.
    Pursuant to Section 19(b)(1) \1\ of the Securities Exchange Act of
1934 (the ``Act '') \2\ and Rule 19b-4 thereunder,\3\ notice is hereby
given that, on April 11, 2008, New York Stock Exchange LLC (``NYSE'' or
the ``Exchange'') filed with the Securities and Exchange Commission
(the ``Commission'') the proposed rule change as described in Items I
and II below, which Items have been substantially prepared by the
Exchange. The Commission is publishing this notice to solicit comments
on the proposed rule change from interested persons and is
simultaneously approving the proposal on an accelerated basis.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 15 U.S.C. 78a.
    \3\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange proposes to amend, retroactively effective to April 7,
2008, NYSE Rule Interpretation 344/02 (Research Analysts and
Supervisory Analysts) concerning research analysts employed by a member
organization's foreign affiliate who contribute to the preparation of
the member organization's research reports. The proposed rule change
conforms NYSE's version of Rule Interpretation 344/02 to approved
amendments filed by the Financial Industry Regulatory Authority, Inc.
(``FINRA'') to its incorporated version of NYSE Rule Interpretation
344/02. The text of the proposed rule change is available on the
Exchange's Web site (http://www.nyse.com), at the Exchange, and at

the Commission's Public Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of, and basis for, the proposed rule change. The
text of those statements may be examined at the places specified in
Item III below. The Exchange has prepared summaries, set forth in
sections A, B, and C below, of the most significant parts of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and the
Statutory Basis for, the Proposed Rule Change

1. Purpose
    On July 30, 2007, NASD and NYSE Regulation, Inc. consolidated their
member firm regulation operations into a combined organization,
FINRA.\4\ Pursuant to FINRA's new regulatory responsibilities, FINRA
amended FINRA's incorporated NYSE Rule Interpretation 344/02 concerning
research analysts employed by a member organization's foreign affiliate
who contribute to the preparation of the member organization's research
reports.\5\ The NYSE proposes to amend its version of Rule
Interpretation 344/02 in order to ensure it remains consistent with the
recently approved changes to FINRA's incorporated NYSE Rule
Interpretation 344/02. The effective date of the proposed rule change
is April 7, 2008, which is the operative date of FINRA's identical
amendments to its incorporated version of NYSE Rule Interpretation 344/
02.
---------------------------------------------------------------------------

    \4\ Pursuant to Rule 17d-2 under the Act, NYSE, NYSE Regulation,
Inc., and NASD entered into an agreement (the ``Agreement'') to
reduce regulatory duplication for firms that are members of FINRA
and also members of NYSE on or after July 30, 2007 (``Dual
Members''), by allocating to FINRA certain regulatory
responsibilities for selected NYSE rules. The Agreement includes a
list of all of those rules (``Common Rules'') for which FINRA has
assumed regulatory responsibilities. See Securities Exchange Act
Release No. 56148 (July 26, 2007), 72 FR 42146 (August 1, 2007)
(File No. 4-544) (Notice of Filing and Order Approving and Declaring
Effective a Plan for the Allocation of Regulatory Responsibilities).
The Common Rules are the same NYSE rules that FINRA has incorporated
into its rulebook. See Securities Exchange Act Release No. 56417
(July 26, 2007), 72 FR 42166 (August 1, 2007) (SR-NASD-2007-054)
(Notice of Filing and Order Granting Accelerated Approval of
Proposed Rule Change to Incorporate Certain NYSE Rules Relating to
Member Firm Conduct). Paragraph 2(b) of the 17d-2 Agreement sets
forth procedures regarding proposed changes by either NYSE or FINRA
to the substance of any of the Common Rules.
    \5\ See Securities Exchange Act Release No. 57278 (February 6,
2008), 73 FR 8086 (February 12, 2008) (SR-FINRA-2007-010). See also
Securities Exchange Act Release No. 57622 (April 4, 2008), 73 FR
19916 (April 11, 2008) (SR-FINRA-2008-012) (discussing further non-
substantive, technical amendments to the text for incorporated NYSE
Rule Interpretation 344/02).
---------------------------------------------------------------------------

2. Statutory Basis
    The Exchange believes the proposed rule change is consistent with
and furthers the objectives of Section 6(b)(5) of the Act,\6\ in that
it is designed to prevent fraudulent and manipulative acts and
practices, to promote just and equitable principles of trade, to remove
impediments to, and perfect the mechanism of, a free and open market
and a national market system, and, in general, to protect investors and
the public interest.
---------------------------------------------------------------------------

    \6\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
impose any burden on competition that is not necessary or appropriate
in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    No written comments were solicited or received with respect to the
proposed rule change.

III. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://
www.sec.gov/rules/sro.shtml); or
     Send an e-mail to<EMAIL_ADDRESS>Please include
File Number SR-NYSE-2008-27 on the subject line.

Paper Comments

     Send paper comments in triplicate to Nancy M. Morris,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-1090.

All submissions should refer to File Number SR-NYSE-2008-27. This file
number should be included on the subject line if e-mail is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's Internet Web site (http://www.sec.gov/rules/
sro.shtml). Copies of the submission, all subsequent amendments, all
written statements with respect to the proposed rule change that are
filed with the Commission, and all written communications relating to
the proposed rule change between the Commission and any person, other
than those that may be withheld from the public in accordance with the
provisions of 5 U.S.C. 552, will be available for inspection and
copying in the Commission's Public Reference Room, 100 F Street, NE.,
Washington, DC 20549-1090, on official business days between the hours
of 10 a.m. and 3 p.m. Copies of the filing will also be available for
inspection and copying at the NYSE's principal office and on its
Internet Web site at http://www.nyse.com. All comments received will be
posted without change; the Commission does not edit personal
identifying information from submissions. You should submit only
information that you wish to make available publicly. All submissions
should refer to File Number SR-NYSE-2008-27 and should be submitted on
or before May 13, 2008.

IV. Commission's Findings and Order Granting Accelerated Approval of
the Proposed Rule Change

    The Commission finds that the proposed rule change is consistent
with the requirements of the Act and the rules and regulations
thereunder applicable to a national securities exchange.\7\ In
particular, the Commission finds that the proposed rule change is
consistent with Section 6(b)(5) of the Act,\8\ which requires, among
other things, that the Exchange's rules be designed to prevent
fraudulent and manipulative acts and practices, to promote just and
equitable principles of trade, to remove impediments to and perfect the
mechanism of a free and open market and a national market system, and,
in general, to protect investors and the public interest.
---------------------------------------------------------------------------

    \7\ In approving this proposal, the Commission has considered
its impact on efficiency, competition, and capital formation. See 15
U.S.C. 78c(f).
    \8\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

    The proposed rule change would make the Exchange's NYSE Rule
Interpretation 344/02 identical to the version that FINRA administers.
The FINRA version was approved by the Commission.\9\ The Commission
also believes that the proposed rule change comports with the
provisions of the

17d-2 Agreement, as approved by the Commission. In this Agreement,
FINRA and NYSE agreed to promptly propose conforming changes, absent a
disagreement about the substance of a proposed rule change, to ensure
that such rules continue to be Common Rules as defined in the
Agreement. In this regard, the Commission believes it is appropriate
for the proposed rule to be effective retroactively as of April 7,
2008, which is the date FINRA's identical amendments became
effective.\10\
---------------------------------------------------------------------------

    \9\ See supra note 5.
    \10\ FINRA Regulatory Notice 08-15 (April 2008).
---------------------------------------------------------------------------

    The Commission finds good cause, consistent with Section 19(b)(2)
of the Act,\11\ for approving this proposed rule change before the
thirtieth day after publication of notice thereof in the Federal
Register. This approval allows the proposed rule change to take effect
without delay. FINRA's change to its version of NYSE Rule
Interpretation 344/02 was published for comment and approved by the
Commission.\12\ Interested persons were provided the opportunity to
submit comments on rule text that is identical to the Exchange's
proposal, and FINRA responded to those comments that were received. The
Commission believes that the Exchange's proposal raises no new
regulatory or substantive issues.
---------------------------------------------------------------------------

    \11\ 15 U.S.C. 78s(b)(2).
    \12\ See supra note 5.
---------------------------------------------------------------------------

V. Conclusion

    It is therefore ordered, pursuant to Section 19(b)(2) of the
Act,\13\ that the proposed rule change (SR-NYSE-2008-27), be, and it
hereby is, approved on an accelerated basis.
---------------------------------------------------------------------------

    \13\ 15 U.S.C. 78s(b)(2).

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\14\
---------------------------------------------------------------------------

    \14\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Florence E. Harmon,
Deputy Secretary.
[FR Doc. E8-8601 Filed 4-21-08; 8:45 am]

BILLING CODE 8010-01-P


[Federal Register Volume 85, Number 133 (Friday, July 10, 2020)]
[Notices]
[Pages 41591-41593]
[FR Doc No: 2020-14878]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2020-N-1391]

Office of Women's Health Strategic Priorities; Establishment of a
Public Docket; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; establishment of a public docket; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is opening a
public docket to solicit input and comments from stakeholders
interested in informing strategic priorities for the Office of Women's
Health (OWH). This will help the Agency ensure that important health
concerns are carefully considered in establishing OWH's scientific,
educational, and outreach priorities.

DATES: Submit either electronic or written comments by September 8,
2020.

ADDRESSES: You may submit comments as follows. Please note that
untimely comments will not be considered. Electronic comments must be
submitted on or before September 8, 2020. The https://www.regulations.gov electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of September 8, 2020. Comments
received by mail/hand delivery/courier (for written/paper submissions)
will be considered timely if they are postmarked or the delivery
service acceptance receipt is on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted,

such as medical information, your or anyone else's Social Security
number, or confidential business information, such as a manufacturing
process. Please note that if you include your name, contact
information, or other information that identifies you in the body of
your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2020-N-1391 for ``Office of Women's Health Strategic Priorities;
Establishment of a Public Docket; Request for Comments.'' Received
comments, those filed in a timely manner (see ADDRESSES), will be
placed in the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at https://www.regulations.gov or at
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through
Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' FDA will review
this copy, including the claimed confidential information, in its
consideration of comments. The second copy, which will have the claimed
confidential information redacted/blacked out, will be available for
public viewing and posted on https://www.regulations.gov. Submit both
copies to the Dockets Management Staff. If you do not wish your name
and contact information be made publicly available, you can provide
this information on the cover sheet and not in the body of your
comments and you must identify the information as ``confidential.'' Any
information marked as ``confidential'' will not be disclosed except in
accordance with 21 CFR 10.20 and other applicable disclosure law. For
more information about FDA's posting of comments to public dockets, see
80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Lisa Lineberger, Food and Drug
Administration, Office of the Commissioner, Office of Women's Health,
10903 New Hampshire Ave., Bldg. 32, Rm. 2333, Silver Spring, MD 20993,
301-796-8751<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. Background

    FDA's OWH was established by Congressional mandate in 1994 as part
of the Office of the Commissioner. The mission of the OWH is to:
     Provide leadership and policy direction for the Agency
related to women's health and coordinate efforts to establish and
advance a women's health agenda for the Agency.
     promote the inclusion of women in clinical trials, the
implementation of guidelines concerning the representation of women in
clinical trials, and the incorporation of sex and gender considerations
into clinical trial data analysis.
     identify and monitor the progress of crosscutting and
multidisciplinary women's health initiatives including changing needs,
areas that require study, and new challenges to the health of women as
they relate to FDA's mission.
     serve as the Agency's liaison with other agencies,
industry, professional associations, and advocacy groups with regards
to the health of women.
    OWH achieves its mission through the foundational principle that
sex as a biological variable should be factored into research design,
analysis, reporting, and education. To this end, OWH supports FDA's
regulatory mission by funding and engaging in intramural and extramural
scientific research and collaborating with stakeholders on educational
and outreach projects. More information on OWH research and educational
activities is available at https://www.fda.gov/science-research/science-and-research-special-topics/womens-health-research.
    OWH recognizes the unique role FDA can play in protecting and
promoting women's health and the value of considering input from
consumers, health professionals, and other stakeholders as it works
toward this goal. Therefore, FDA is issuing this Federal Register
notice to open Docket No. FDA-2020-N-1391 for the public to submit
comments. FDA will take the suggestions and information submitted to
the docket into consideration when developing OWH scientific,
educational, and outreach priorities.

II. Issues for Consideration

    To maximize FDA OWH's ability to promote, protect, and advance the
health of women, we are seeking input on research priorities driven by
data gaps and areas of unmet need; topics for education among
consumers, health professionals, and other stakeholders; and outreach
to women, especially underserved and diverse populations. We are also
interested in proposed methods for acting on these priorities, such as
collaborations and partnerships. In particular, OWH requests comments
on:
     Efforts to encourage analysis and detection of potential
sex and gender differences in the safety, efficacy, and use of FDA-
regulated products.
     efforts to anticipate, meet, and respond to existing and
emerging issues related to women's health and FDA-regulated products.
     direct outreach to diverse groups of women to promote
access to relevant information about FDA-regulated products, encourage
participation in clinical trials, and maintain dialogue about critical
women's health topics.
     coordination and collaboration with other Federal Agencies
and external stakeholders to support research and programming on
women's health topics.
     identification of regulatory decisions that can benefit
from participation of women across the lifespan (e.g., reproductive-age
women, pregnant women, post-menopausal women, and elderly women) and
women with certain health conditions.
     generation of research and programming topics, interests,
and areas of focus that predominantly affect

women and/or would benefit from sex- and gender-related analyses.

    Dated: July 6, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-14878 Filed 7-9-20; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register Volume 85, Number 3 (Monday, January 6, 2020)]
[Notices]
[Pages 538-545]
[FR Doc No: 2019-28491]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Investment Company Act Release No. 33739; 812-15040]

Fundrise Real Estate Interval Fund, LLC, et al.

December 31, 2019.
AGENCY: Securities and Exchange Commission (``Commission'').

ACTION: Notice.

-----------------------------------------------------------------------

    Notice of application for an order (``Order'') under section 17(d)
of the Investment Company Act of 1940 (the ``Act'') and rule 17d-1
under the Act to permit certain joint transactions otherwise prohibited
by section 17(d) of the Act and rule 17d-1 under the Act.

ADDRESSES: Secretary, U.S. Securities and Exchange Commission, 100 F
Street, NE, Washington, DC 20549-1090. Applicants: 11 Dupont Circle NW,
9th Floor, Washington, DC 20036.

FOR FURTHER INFORMATION CONTACT: Bruce R. MacNeil, Senior Counsel, at
202-551-6817, or Kaitlin C. Bottock, Branch Chief, at<PHONE_NUMBER>
(Division of Investment Management, Chief Counsel's Office).

SUPPLEMENTARY INFORMATION:

Summary of Application: Applicants request an order to permit certain
closed-end management investment companies to co-invest in portfolio
companies with each other and with affiliated investment funds and
accounts.

Applicants: Fundrise Real Estate Interval Fund, LLC (the ``Company''),
Fundrise Real Estate Investment Trust, LLC, Fundrise Equity REIT, LLC,
Fundrise Income eREIT II, LLC, Fundrise Income eREIT III, LLC, Fundrise
Income eREIT 2019, LLC, Fundrise Growth eREIT II, LLC, Fundrise Growth
eREIT III, LLC, Fundrise Growth eREIT 2019, LLC, Fundrise Midland
Opportunistic REIT, LLC, Fundrise West Coast Opportunistic REIT, LLC,
Fundrise East Coast Opportunistic REIT, LLC, Fundrise For-Sale Housing
eFUND--Los Angeles CA, LLC, Fundrise For-Sale Housing eFUND--Washington
DC, LLC, Fundrise National For-Sale Housing eFund, LLC, Fundrise
Opportunity Fund, LP, (the ``Existing Affiliated Funds''), Fundrise
Advisors, LLC (``FA'') and Fundrise Lending LLC.

Filing Dates: The application was filed on June 11, 2019, and amended
on September 4, 2019, and November 26, 2019.

Hearing or Notification of Hearing: An order granting the requested
relief will be issued unless the Commission orders a hearing.
Interested persons may request a hearing by writing to the Commission's
Secretary and serving applicants with a copy of the request, personally
or by mail. Hearing requests should be received by the Commission by
5:30 p.m. on January 24, 2020, and should be accompanied by proof of
service on applicants, in the form of an affidavit or, for lawyers, a
certificate of service. Pursuant to rule 0-5 under the Act, hearing
requests should state the nature of the writer's interest, any facts
bearing upon the desirability of a hearing on the matter, the reason
for the request, and the issues contested. Persons who wish to be
notified of a hearing may request notification by writing to the
Commission's Secretary.
    The following is a summary of the application. The complete
application may be obtained via the Commission's website by searching
for the file number, or for an applicant using the Company name box, at
http://www.sec.gov/search/search.htm or by calling<PHONE_NUMBER>.

Introduction

    1. The applicants request an order of the Commission under section
17(d) of the Act and rule 17d-1 under the Act to permit, subject to the
terms and conditions set forth in the application (the ``Conditions''),
one or more Regulated Funds \1\ and/or one or more

Affiliated Funds \2\ to enter into Co-Investment Transactions with each
other. ``Co-Investment Transaction'' means any transaction in which one
or more Regulated Funds (or its Wholly-Owned Investment Sub (defined
below) participated together with one or more Affiliated Funds and/or
one or more other Regulated Funds in reliance on the Order. ``Potential
Co-Investment Transaction'' means any investment opportunity in which a
Regulated Fund (or its Wholly-Owned Investment Sub) could not
participate together with one or more Affiliated Funds and/or one or
more other Regulated Funds without obtaining and relying on the
Order.\3\
---------------------------------------------------------------------------

    \1\ ``Regulated Funds'' means the Company and the Future
Regulated Funds. ``Future Regulated Fund'' means a closed-end
management investment company (a) that is registered under the Act,
(b) whose investment adviser is an Adviser, and (c) that intends to
participate in the proposed co-investment program (the ``Co-
Investment Program'').
     ``Adviser'' means FA together with any future investment
adviser that (i) controls, is controlled by or is under common
control with FA, (ii) is registered as an investment adviser under
the Investment Advisers Act of 1940 (the ``Advisers Act'') and (iii)
is not a Regulated Fund or a subsidiary of a Regulated Fund.
    \2\ ``Affiliated Fund'' means any Existing Affiliated Fund, any
Future Affiliated Fund or any Fundrise Proprietary Account. ``Future
Affiliated Fund'' means any entity (a) whose investment adviser is
an Adviser, (b) (i) that would be an investment company but for
Section 3(c)(1), 3(c)(5)(C) or 3(c)(7) of the Act or (ii) that does
not meet the definition of investment company under the Act and
qualifies as a real estate investment company (``REIT'') within the
meaning of Section 856 of the Internal Revenue Code (``Code'')
because substantially all of its assets would consist of real
properties, and (c) that intends to participate in the Co-Investment
Program. ``Fundrise Proprietary Account'' means Fundrise Lending
LLC, and any direct or indirect, wholly- or majority-owned
subsidiary of FA that is formed in the future that, from time to
time, may hold various financial assets in a principal capacity.
    \3\ All existing entities that currently intend to rely on the
Order have been named as applicants and any existing or future
entities that may rely on the Order in the future will comply with
the terms and Conditions set forth in the application.
---------------------------------------------------------------------------

Applicants

    2. The Company is a Delaware limited liability company organized as
a non-diversified closed-end management investment company that
operates as an interval fund pursuant to rule 23c3 under the Act. The
Company has elected to be treated as a REIT under Sub-Chapter M of the
Code, and intends to continue to maintain its qualification as a REIT
in the future. The Company is managed by a Board \4\ currently
comprised of four persons, three of whom are Independent Directors.\5\
---------------------------------------------------------------------------

    \4\ ``Board'' means the board of directors (or the equivalent)
of the applicable Regulated Fund.
    \5\ ``Independent Director'' means a member of the Board of any
relevant entity who is not an ``interested person'' as defined in
section 2(a)(19) of the Act. No Independent Director of a Regulated
Fund will have a financial interest in any Co-Investment
Transaction, other than indirectly through share ownership in one of
the Regulated Funds.
---------------------------------------------------------------------------

    3. FA, a Delaware limited liability company that is registered
under the Advisers Act, serves as the investment adviser to the Company
pursuant to an investment advisory agreement. FA also serves as
investment adviser to each Existing Affiliated Fund.
    4. Fundrise Lending LLC, an affiliate under common control with FA,
holds various financial assets in a principal capacity. Fundrise
Lending, LLC also originates real estate loans.
    5. Applicants represent that each Existing Affiliated Fund is a
separate and distinct legal entity and each of which (i) would be an
investment company but for Section 3(c)(1), 3(c)(5)(C) or 3(c)(7) of
the Act, or (ii) does not meet the definition of investment company
under the Act and qualifies as a REIT within the meaning of Section 856
of the Code because substantially all of its assets would consist of
real properties.
    6. Applicants state that a Regulated Fund may, from time to time,
form one or more Wholly-Owned Investment Subs.\6\ Such a subsidiary may
be prohibited from investing in a Co-Investment Transaction with a
Regulated Fund (other than its parent) or any Affiliated Fund because
it would be a company controlled by its parent Regulated Fund for
purposes of rule 17d-1. Applicants request that each Wholly-Owned
Investment Sub be permitted to participate in Co-Investment
Transactions in lieu of the Regulated Fund that owns it and that the
Wholly-Owned Investment Sub's participation in any such transaction be
treated, for purposes of the Order, as though the parent Regulated Fund
were participating directly.
---------------------------------------------------------------------------

    \6\ ``Wholly-Owned Investment Sub'' means an entity (i) that is
a wholly-owned subsidiary of a Regulated Fund (with such Regulated
Fund at all times holding, beneficially and of record, 100% of the
voting and economic interests); (ii) whose sole business purpose is
to hold one or more investments on behalf of such Regulated Fund;
(iii) with respect to which such Regulated Fund's Board has the sole
authority to make all determinations with respect to the entity's
participation under the Conditions to the application; and (iv) (A)
would be an investment company but for Section 3(c)(1), 3(c)(5)(C),
or 3(c)(7) of the Act, or (B) qualifies as a REIT within the meaning
of Section 856 of the Code because substantially all of its assets
would consist of real properties.
---------------------------------------------------------------------------

Applicants' Representations

A. Allocation Process

    7. Applicants represent that FA has established processes for
allocating initial investment opportunities, opportunities for
subsequent investments in an issuer and dispositions of securities
holdings reasonably designed to treat all clients fairly and equitably.
Further, applicants represent that these processes will be extended and
modified in a manner reasonably designed to ensure that the additional
transactions permitted under the Order will both (i) be fair and
equitable to the Regulated Funds and the Affiliated Funds and (ii)
comply with the Conditions.
    8. If the requested Order is granted, the Adviser will establish,
maintain and implement policies and procedures reasonably designed to
ensure that when such opportunities arise, the Adviser to the relevant
Regulated Funds is promptly notified and receives the same information
about the opportunity as any other Adviser considering the opportunity
for its clients. In particular, consistent with Condition 1, if a
Potential Co-Investment Transaction falls within the then-current
Objectives and Strategies \7\ and any Board-Established Criteria \8\ of
a Regulated Fund, the policies and procedures will require that the
Adviser to such Regulated Fund receive sufficient information to allow
such Adviser's investment committee to make its independent
determination and recommendations under the Conditions.
---------------------------------------------------------------------------

    \7\ ``Objectives and Strategies'' means a Regulated Fund's
investment objectives and strategies, as described in its most
current registration statement on Form N-2, other current filings
with the Commission under the Securities Act of 1933 (the
``Securities Act'') or under the Securities Exchange Act of 1934, as
amended, and its most current report to stockholders.
    \8\ ``Board-Established Criteria'' means criteria that the Board
of a Regulated Fund may establish from time to time to describe the
characteristics of Potential Co-Investment Transactions regarding
which the Adviser to such Regulated Fund should be notified under
Condition 1. The Board-Established Criteria will be consistent with
the Regulated Fund's Objectives and Strategies. If no Board-
Established Criteria are in effect, then the Regulated Fund's
Adviser will be notified of all Potential Co-Investment Transactions
that fall within the Regulated Fund's then-current Objectives and
Strategies. Board-Established Criteria will be objective and
testable, meaning that they will be based on observable information,
such as industry/sector of the issuer, minimum EBITDA of the issuer,
asset class of the investment opportunity or required commitment
size, and not on characteristics that involve a discretionary
assessment. The Adviser to the Regulated Fund may from time to time
recommend criteria for the Board's consideration, but Board-
Established Criteria will only become effective if approved by a
majority of the Independent Directors. The Independent Directors of
a Regulated Fund may at any time rescind, suspend or qualify its
approval of any Board-Established Criteria, though Applicants
anticipate that, under normal circumstances, the Board would not
modify these criteria more often than quarterly.
---------------------------------------------------------------------------

    9. The Adviser to each applicable Regulated Fund will then make an
independent determination of the appropriateness of the investment for
the Regulated Fund in light of the Regulated Fund's then-current
circumstances. If the Adviser to a Regulated Fund deems the Regulated
Fund's participation in any Potential

Co-Investment Transaction to be appropriate, then it will formulate a
recommendation regarding the proposed order amount for the Regulated
Fund.
    10. Applicants state that, for each Regulated Fund and Affiliated
Fund whose Adviser recommends participating in a Potential Co-
Investment Transaction, such Adviser's investment committee will
approve an investment amount to be allocated to each Regulated Fund
and/or Affiliated Fund participating in the Potential Co-Investment
Transaction. Applicants state further that, each proposed order amount
may be reviewed and adjusted, in accordance with the Adviser's written
allocation policies and procedures, by the Adviser's investment
committee.\9\ The order of a Regulated Fund or Affiliated Fund
resulting from this process is referred to as its ``Internal Order.''
The Internal Order will be submitted for approval by the Required
Majority of any participating Regulated Funds in accordance with the
Conditions.\10\
---------------------------------------------------------------------------

    \9\ The reason for any such adjustment to a proposed order
amount will be documented in writing and preserved in the records of
each Adviser.
    \10\ ``Required Majority'' means a required majority, as defined
in section 57(o) of the Act. Although each Regulated Fund will be a
registered closed-end fund, the Board members that make up the
Required Majority will be determined as if the Regulated Fund were a
business development company subject to section 57(o) (``BDC'').
---------------------------------------------------------------------------

    11. If the aggregate Internal Orders for a Potential Co-Investment
Transaction do not exceed the size of the investment opportunity
immediately prior to the submission of the orders to the underwriter,
broker, dealer or issuer, as applicable (the ``External Submission''),
then each Internal Order will be fulfilled as placed. If, on the other
hand, the aggregate Internal Orders for a Potential Co-Investment
Transaction exceed the size of the investment opportunity immediately
prior to the External Submission, then the allocation of the
opportunity will be made pro rata on the basis of the size of the
Internal Orders.\11\ If, subsequent to such External Submission, the
size of the opportunity is increased or decreased, or if the terms of
such opportunity, or the facts and circumstances applicable to the
Regulated Funds' or the Affiliated Funds' consideration of the
opportunity, change, the participants will be permitted to submit
revised Internal Orders in accordance with written allocation policies
and procedures that the Advisers will establish, implement and
maintain.\12\
---------------------------------------------------------------------------

    \11\ The Advisers will maintain records of all proposed order
amounts, Internal Orders and External Submissions in conjunction
with Potential Co-Investment Transactions. Each applicable Adviser
will provide the Eligible Directors with information concerning the
Affiliated Funds' and Regulated Funds' order sizes to assist the
Eligible Directors with their review of the applicable Regulated
Fund's investments for compliance with the Conditions. ``Eligible
Directors'' means, with respect to a Regulated Fund and a Potential
Co-Investment Transaction, the members of the Regulated Fund's Board
eligible to vote on that Potential Co-Investment Transaction as if
the Regulated Fund were a BDC subject to section 57(o) of the Act.
    \12\ The Board of the Regulated Fund will then either approve or
disapprove of the investment opportunity in accordance with
Condition 2, 6, 7, 8 or 9, as applicable.
---------------------------------------------------------------------------

B. Follow-On Investments

    12. Applicants state that from time to time the Regulated Funds and
Affiliated Funds may have opportunities to make Follow-On Investments
\13\ in an issuer in which a Regulated Fund and one or more other
Regulated Funds and/or Affiliated Funds previously have invested.
---------------------------------------------------------------------------

    \13\ ``Follow-On Investment'' means an additional investment in
the same issuer, including, but not limited to, through the exercise
of warrants, conversion privileges or other rights to purchase
securities of the issuer.
---------------------------------------------------------------------------

    13. Applicants propose that Follow-On Investments would be divided
into two categories depending on whether the prior investment was a Co-
Investment Transaction or a Pre-Boarding Investment.\14\ If the
Regulated Funds and Affiliated Funds have previously participated in a
Co-Investment Transaction with respect to the issuer, then the terms
and approval of the Follow-On Investment would be subject to the
Standard Review Follow-Ons described in Condition 8. If the Regulated
Funds and Affiliated Funds have not previously participated in a Co-
Investment Transaction with respect to the issuer but hold a Pre-
Boarding Investment, then the terms and approval of the Follow-On
Investment would be subject to the Enhanced-Review Follow-Ons described
in Condition 9. All Enhanced Review Follow-Ons require the approval of
the Required Majority. For a given issuer, the participating Regulated
Funds and Affiliated Funds need to comply with the requirements of
Enhanced-Review Follow-Ons only for the first Co-Investment
Transaction. Subsequent Co-Investment Transactions with respect to the
issuer would be governed by the requirements of Standard Review Follow-
Ons.
---------------------------------------------------------------------------

    \14\ ``Pre-Boarding Investments'' are investments in an issuer
held by a Regulated Fund as well as one or more Affiliated Funds
and/or one or more other Regulated Funds that were acquired prior to
participating in any Co-Investment Transaction: (i) In transactions
in which the only term negotiated by or on behalf of such funds was
price in reliance on one of the JT No-Action Letters (defined
below); or (ii) in transactions occurring at least 90 days apart and
without coordination between the Regulated Fund and any Affiliated
Fund or other Regulated Fund.
---------------------------------------------------------------------------

    14. A Regulated Fund would be permitted to invest in Standard
Review Follow-Ons either with the approval of the Required Majority
under Condition 8(c) or without Board approval under Condition 8(b) if
it is (i) a Pro Rata Follow-On Investment \15\ or (ii) a Non-Negotiated
Follow-On Investment.\16\ Applicants believe that these Pro Rata and
Non-Negotiated Follow-On Investments do not present a significant
opportunity for overreaching on the part of any Adviser and thus do not
warrant the time or the attention of the Board. Pro Rata Follow-On
Investments and Non-Negotiated Follow-On Investments remain subject to
the Board's periodic review in accordance with Condition 10.
---------------------------------------------------------------------------

    \15\ A ``Pro Rata Follow-On Investment'' is a Follow-On
Investment (i) in which the participation of each Affiliated Fund
and each Regulated Fund is proportionate to its outstanding
investments in the issuer or security, as appropriate, immediately
preceding the Follow-On Investment, and (ii) in the case of a
Regulated Fund, a majority of the Board has approved the Regulated
Fund's participation in the pro rata Follow-On Investments as being
in the best interests of the Regulated Fund. The Regulated Fund's
Board may refuse to approve, or at any time rescind, suspend or
qualify, its approval of Pro Rata Follow-On Investments, in which
case all subsequent Follow-On Investments will be submitted to the
Regulated Fund's Eligible Directors in accordance with Condition
8(c).
    \16\ A ``Non-Negotiated Follow-On Investment'' is a Follow-On
Investment in which a Regulated Fund participates together with one
or more Affiliated Funds and/or one or more other Regulated Funds
(i) in which the only term negotiated by or on behalf of the funds
is price and (ii) with respect to which, if the transaction were
considered on its own, the funds would be entitled to rely on one of
the JT No-Action Letters.
    ``JT No-Action Letters'' means SMC Capital, Inc., SEC No-Action
Letter (pub. avail. Sept. 5, 1995) and Massachusetts Mutual Life
Insurance Company, SEC No-Action Letter (pub. avail. June 7, 2000).
---------------------------------------------------------------------------

C. Dispositions

    15. Applicants propose that Dispositions \17\ would be divided into
two categories. If the Regulated Funds and Affiliated Funds holding
investments in the issuer have previously participated in a Co-
Investment Transaction with respect to the issuer, then the terms and
approval of the Disposition would be subject to the Standard Review
Dispositions described in Condition 6. If the Regulated Funds and
Affiliated Funds have not previously participated in a Co-Investment
Transaction with respect to the issuer but hold a Pre-Boarding
Investment, then the terms and approval of the Disposition would be
subject to the Enhanced Review Dispositions described in Condition 7.
Subsequent

Dispositions with respect to the same issuer would be governed by
Condition 6 under the Standard Review Dispositions.\18\
---------------------------------------------------------------------------

    \17\ ``Disposition'' means the sale, exchange or other
disposition of an interest in a security of an issuer.
    \18\ However, with respect to an issuer, if a Regulated Fund's
first Co-Investment Transaction is an Enhanced Review Disposition,
and the Regulated Fund does not dispose of its entire position in
the Enhanced Review Disposition, then before such Regulated Fund may
complete its first Standard Review Follow-On in such issuer, the
Eligible Directors must review the proposed Follow-On Investment not
only on a stand-alone basis but also in relation to the total
economic exposure in such issuer (i.e., in combination with the
portion of the Pre-Boarding Investment not disposed of in the
Enhanced Review Disposition), and the other terms of the
investments. This additional review is required because such
findings were not required in connection with the prior Enhanced
Review Disposition, but they would have been required had the first
Co-Investment Transaction been an Enhanced Review Follow-On.
---------------------------------------------------------------------------

    16. A Regulated Fund may participate in a Standard Review
Disposition either with the approval of the Required Majority under
Condition 6(d) or without Board approval under Condition 6(c) if (i)
the Disposition is a Pro Rata Disposition \19\ or (ii) the securities
are Tradable Securities \20\ and the Disposition meets the other
requirements of Condition 6(c)(ii). Pro Rata Dispositions and
Dispositions of a Tradable Security remain subject to the Board's
periodic review in accordance with Condition 10.
---------------------------------------------------------------------------

    \19\ A ``Pro Rata Disposition'' is a Disposition (i) in which
the participation of each Affiliated Fund and each Regulated Fund is
proportionate to its outstanding investment in the security subject
to Disposition immediately preceding the Disposition; and (ii) in
the case of a Regulated Fund, a majority of the Board has approved
the Regulated Fund's participation in pro rata Dispositions as being
in the best interests of the Regulated Fund. The Regulated Fund's
Board may refuse to approve, or at any time rescind, suspend or
qualify, its approval of Pro Rata Dispositions, in which case all
subsequent Dispositions will be submitted to the Regulated Fund's
Eligible Directors.
    \20\ ``Tradable Security'' means a security that meets the
following criteria at the time of Disposition: (i) It trades on a
national securities exchange or designated offshore securities
market as defined in rule 902(b) under the Securities Act; (ii) it
is not subject to restrictive agreements with the issuer or other
security holders; and (iii) it trades with sufficient volume and
liquidity (findings as to which are documented by the Advisers to
any Regulated Funds holding investments in the issuer and retained
for the life of the Regulated Fund) to allow each Regulated Fund to
dispose of its entire position remaining after the proposed
Disposition within a short period of time not exceeding 30 days at
approximately the value (as defined by section 2(a)(41) of the Act)
at which the Regulated Fund has valued the investment.
---------------------------------------------------------------------------

D. Delayed Settlement

    17. Applicants represent that under the terms and Conditions of the
application, all Regulated Funds and Affiliated Funds participating in
a Co-Investment Transaction will invest at the same time, for the same
price and with the same terms, conditions, class, registration rights
and any other rights, so that none of them receives terms more
favorable than any other. However, the settlement date for an
Affiliated Fund in a Co-Investment Transaction may occur up to ten
business days after the settlement date for the Regulated Fund, and
vice versa. Nevertheless, in all cases, (i) the date on which the
commitment of the Affiliated Funds and Regulated Funds is made will be
the same even where the settlement date is not and (ii) the earliest
settlement date and the latest settlement date of any Affiliated Fund
or Regulated Fund participating in the transaction will occur within
ten business days of each other.

E. Holders

    18. Under Condition 15, if an Adviser, its principals, or any
person controlling, controlled by, or under common control with the
Adviser or its principals, and the Affiliated Funds (collectively, the
``Holders'') own in the aggregate more than 25 percent of the
outstanding voting shares of a Regulated Fund (the ``Shares''), then
the Holders will vote such Shares as directed by an independent third
party when voting on matters specified in the Condition. Applicants
believe that this Condition will ensure that the Independent Directors
will act independently in evaluating Co-Investment Transactions,
because the ability of the Adviser or its principals to influence the
Independent Directors by a suggestion, explicit or implied, that the
Independent Directors can be removed will be limited significantly. The
Independent Directors shall evaluate and approve any independent party,
taking into account its qualifications, reputation for independence,
cost to the shareholders, and other factors that they deem relevant.

Applicants' Legal Analysis

    1. Section 17(d) of the Act and rule 17d-1 under the Act prohibit
participation by a registered investment company and an affiliated
person in any ``joint enterprise or other joint arrangement or profit-
sharing plan,'' as defined in the rule, without prior approval by the
Commission by order upon application.
    2. Co-Investment Transactions are prohibited by rule 17d-1 without
a prior exemptive order of the Commission to the extent that the
Affiliated Funds and the Regulated Funds participating in such
transactions fall within the category of persons described by rule 17d-
1, vis-[agrave]-vis each participating Regulated Fund. Each of the
participating Regulated Funds and Affiliated Funds may be deemed to be
affiliated persons vis-[agrave]-vis a Regulated Fund within the meaning
of section 2(a)(3) by reason of common control because (i) the Adviser
manages each of the Affiliated Funds and may be deemed to control any
Future Regulated Fund and any Future Affiliated Fund, and (ii) the
Adviser manages the Company pursuant its investment advisory agreement.
Thus, each of the Affiliated Funds could be deemed to be a person
related to the Company and the Future Regulated Funds in a manner
described by rule 17d-1; and therefore the prohibitions of rule 17d-1
would apply respectively to prohibit the Affiliated Funds from
participating in Co-Investment Transactions with the Regulated Funds.
Each Regulated Fund would also be related to each other Regulated Fund
in a manner described by rule 17d-1, and thus prohibited from
participating in Co-Investment Transactions with each other. In
addition, because the Fundrise Proprietary Accounts are controlled by,
or under common control with, FA and, therefore, may be under common
control with the Company, any future Advisers, and any Future Regulated
Funds, the Fundrise Proprietary Accounts could be prohibited from
participating in the Co-Investment Program.
    3. In passing upon applications under rule 17d-1, the Commission
considers whether the company's participation in the joint transaction
is consistent with the provisions, policies, and purposes of the Act
and the extent to which such participation is on a basis different from
or less advantageous than that of other participants.
    4. Applicants state that in the absence of the requested relief, in
many circumstances the Regulated Funds would be limited in their
ability to participate in attractive and appropriate investment
opportunities. Applicants state that, as required by rule 17d-1(b), the
Conditions ensure that the terms on which Co-Investment Transactions
may be made will be consistent with the participation of the Regulated
Funds being on a basis that it is neither different from nor less
advantageous than other participants, thus protecting the equity
holders of any participant from being disadvantaged. Applicants further
state that the Conditions ensure that all Co-Investment Transactions
are reasonable and fair to the Regulated Funds and their shareholders
and do not involve overreaching by any person concerned, including the
Advisers. Applicants state that the Regulated Funds' participation in
the Co-Investment Transactions in accordance

with the Conditions will be consistent with the provisions, policies,
and purposes of the Act and would be done in a manner that is not
different from, or less advantageous than, that of other participants.

Applicants' Conditions

    Applicants agree that the Order will be subject to the following
Conditions:
    1. Identification and Referral of Potential Co-Investment
Transactions.
    (a). The Advisers will establish, maintain and implement policies
and procedures reasonably designed to ensure that each Adviser is
promptly notified of all Potential Co-Investment Transactions that fall
within the then-current Objectives and Strategies and Board-Established
Criteria of any Regulated Fund the Adviser manages.
    (b). When an Adviser to a Regulated Fund is notified of a Potential
Co-Investment Transaction under Condition 1(a), the Adviser will make
an independent determination of the appropriateness of the investment
for the Regulated Fund in light of the Regulated Fund's then-current
circumstances.
    2. Board Approvals of Co-Investment Transactions.
    (a). If the Adviser deems a Regulated Fund's participation in any
Potential Co-Investment Transaction to be appropriate for the Regulated
Fund, it will then determine an appropriate level of investment for the
Regulated Fund.
    (b). If the aggregate amount recommended by the Advisers to be
invested in the Potential Co-Investment Transaction by the
participating Regulated Funds and any participating Affiliated Funds,
collectively, exceeds the amount of the investment opportunity, the
investment opportunity will be allocated among them pro rata based on
the size of the Internal Orders, as described in section III.A.1.b. of
the application. Each Adviser to a participating Regulated Fund will
promptly notify and provide the Eligible Directors with information
concerning the Affiliated Funds' and Regulated Funds' order sizes to
assist the Eligible Directors with their review of the applicable
Regulated Fund's investments for compliance with these Conditions.
    (c). After making the determinations required in Condition 1(b)
above, each Adviser to a participating Regulated Fund will distribute
written information concerning the Potential Co-Investment Transaction
(including the amount proposed to be invested by each participating
Regulated Fund and each participating Affiliated Fund) to the Eligible
Directors of its participating Regulated Fund(s) for their
consideration. A Regulated Fund will enter into a Co-Investment
Transaction with one or more other Regulated Funds or Affiliated Funds
only if, prior to the Regulated Fund's participation in the Potential
Co-Investment Transaction, a Required Majority concludes that:
    (i). The terms of the transaction, including the consideration to
be paid, are reasonable and fair to the Regulated Fund and its equity
holders and do not involve overreaching in respect of the Regulated
Fund or its equity holders on the part of any person concerned;
    (ii). the transaction is consistent with:
    (A). The interests of the Regulated Fund's equity holders; and
    (B). the Regulated Fund's then-current Objectives and Strategies;
    (iii). the investment by any other Regulated Fund(s) or Affiliated
Fund(s) would not disadvantage the Regulated Fund, and participation by
the Regulated Fund would not be on a basis different from, or less
advantageous than, that of any other Regulated Fund(s) or Affiliated
Fund(s) participating in the transaction; provided that the Required
Majority shall not be prohibited from reaching the conclusions required
by this Condition 2(c)(iii) if:
    (A). The settlement date for another Regulated Fund or an
Affiliated Fund in a Co-Investment Transaction is later than the
settlement date for the Regulated Fund by no more than ten business
days or earlier than the settlement date for the Regulated Fund by no
more than ten business days, in either case, so long as: (x) The date
on which the commitment of the Affiliated Funds and Regulated Funds is
made is the same; and (y) the earliest settlement date and the latest
settlement date of any Affiliated Fund or Regulated Fund participating
in the transaction will occur within ten business days of each other;
or
    (B). any other Regulated Fund or Affiliated Fund, but not the
Regulated Fund itself, gains the right to nominate a director for
election to a portfolio company's board of directors, the right to have
a board observer or any similar right to participate in the governance
or management of the portfolio company so long as: (x) The Eligible
Directors will have the right to ratify the selection of such director
or board observer, if any; (y) the Adviser agrees to, and does, provide
periodic reports to the Regulated Fund's Board with respect to the
actions of such director or the information received by such board
observer or obtained through the exercise of any similar right to
participate in the governance or management of the portfolio company;
and (z) any fees or other compensation that any other Regulated Fund or
Affiliated Fund or any affiliated person of any other Regulated Fund or
Affiliated Fund receives in connection with the right of one or more
Regulated Funds or Affiliated Funds to nominate a director or appoint a
board observer or otherwise to participate in the governance or
management of the portfolio company will be shared proportionately
among any participating Affiliated Funds (who may, in turn, share their
portion with their affiliated persons) and any participating Regulated
Fund(s) in accordance with the amount of each such party's investment;
and
    (iv). the proposed investment by the Regulated Fund will not
involve compensation, remuneration or a direct or indirect \21\
financial benefit to the Advisers, any other Regulated Fund, the
Affiliated Funds or any affiliated person of any of them (other than
the parties to the Co-Investment Transaction), except (A) to the extent
permitted by Condition 14, (B) to the extent permitted by Section 17
(e), (C) indirectly, as a result of an interest in the securities
issued by one of the parties to the Co-Investment Transaction, or (D)
in the case of fees or other compensation described in Condition
2(c)(iii)(B)(z).
---------------------------------------------------------------------------

    \21\ For example, procuring the Regulated Fund's investment in a
Potential Co-Investment Transaction to permit an affiliate to
complete or obtain better terms in a separate transaction would
constitute an indirect financial benefit.
---------------------------------------------------------------------------

    3. Right to Decline. Each Regulated Fund has the right to decline
to participate in any Potential Co-Investment Transaction or to invest
less than the amount proposed.
    4. General Limitation. Except for Follow-On Investments made in
accordance with Conditions 8 and 9 below,\22\ a Regulated Fund will not
invest in reliance on the Order in any issuer in which a Related Party
has an investment.\23\
---------------------------------------------------------------------------

    \22\ This exception applies only to Follow-On Investments by a
Regulated Fund in issuers in which that Regulated Fund already holds
investments.
    \23\ ``Related Party'' means (i) any Close Affiliate and (ii) in
respect of matters as to which any Adviser has knowledge, any Remote
Affiliate.
     ``Close Affiliate'' means the Advisers, the Regulated Funds,
the Affiliated Funds and any other person described in section 57(b)
(after giving effect to rule 57b-1) in respect of any Regulated Fund
(treating any registered investment company or series thereof as a
BDC for this purpose) except for limited partners included solely by
reason of the reference in section 57(b) to section 2(a)(3)(D).
     ``Remote Affiliate'' means any person described in section
57(e) in respect of any Regulated Fund (treating any registered
investment company or series thereof as a BDC for this purpose) and
any limited partner holding 5% or more of the relevant limited
partner interests that would be a Close Affiliate but for the
exclusion in that definition.

---------------------------------------------------------------------------

    5. Same Terms and Conditions. A Regulated Fund will not participate
in any Potential Co-Investment Transaction unless (i) the terms,
conditions, price, class of securities to be purchased, date on which
the commitment is entered into and registration rights (if any) will be
the same for each participating Regulated Fund and Affiliated Fund and
(ii) the earliest settlement date and the latest settlement date of any
participating Regulated Fund or Affiliated Fund will occur as close in
time as practicable and in no event more than ten business days apart.
The grant to one or more Regulated Funds or Affiliated Funds, but not
the respective Regulated Fund, of the right to nominate a director for
election to a portfolio company's board of directors, the right to have
an observer on the board of directors or similar rights to participate
in the governance or management of the portfolio company will not be
interpreted so as to violate this Condition 5, if Condition
2(c)(iii)(B) is met.
    6. Standard Review Dispositions.
    (a). General. If any Regulated Fund or Affiliated Fund elects to
sell, exchange or otherwise dispose of an interest in a security and
one or more Regulated Funds and Affiliated Funds have previously
participated in a Co-Investment Transaction with respect to the issuer,
then:
    (i). The Adviser to such Regulated Fund or Affiliated Fund \24\
will notify each Regulated Fund that holds an investment in the issuer
of the proposed Disposition at the earliest practical time; and
---------------------------------------------------------------------------

    \24\ Any Fundrise Proprietary Account that is not advised by an
Adviser is itself deemed to be an Adviser for purposes of Conditions
6(a)(i), 7(a)(i), 8(a)(i) and 9(a)(i).
---------------------------------------------------------------------------

    (ii). the Adviser to each Regulated Fund that holds an investment
in the issuer will formulate a recommendation as to participation by
such Regulated Fund in the Disposition.
    (b). Same Terms and Conditions. Each Regulated Fund will have the
right to participate in such Disposition on a proportionate basis, at
the same price and on the same terms and conditions as those applicable
to the Affiliated Funds and any other Regulated Fund.
    (c). No Board Approval Required. A Regulated Fund may participate
in such a Disposition without obtaining prior approval of the Required
Majority if:
    (i). (A) The participation of each Regulated Fund and Affiliated
Fund in such Disposition is proportionate to its then-current holding
of the security (or securities) of the issuer that is (or are) the
subject of the Disposition; \25\ (B) the Board of the Regulated Fund
has approved as being in the best interests of the Regulated Fund the
ability to participate in such Dispositions on a pro rata basis (as
described in greater detail in the application); and (C) the Board of
the Regulated Fund is provided on a quarterly basis with a list of all
Dispositions made in accordance with this Condition; or
---------------------------------------------------------------------------

    \25\ In the case of any Disposition, proportionality will be
measured by each participating Regulated Fund's and Affiliated
Fund's outstanding investment in the security in question
immediately preceding the Disposition.
---------------------------------------------------------------------------

    (ii). each security is a Tradable Security and (A) the Disposition
is not to the issuer or any affiliated person of the issuer; and (B)
the security is sold for cash in a transaction in which the only term
negotiated by or on behalf of the participating Regulated Funds and
Affiliated Funds is price.
    (d). Standard Board Approval. In all other cases, the Adviser will
provide its written recommendation as to the Regulated Fund's
participation to the Eligible Directors and the Regulated Fund will
participate in such Disposition solely to the extent that a Required
Majority determines that it is in the Regulated Fund's best interests.
    7. Enhanced Review Dispositions.
    (a). General. If any Regulated Fund or Affiliated Fund elects to
sell, exchange or otherwise dispose of a Pre-Boarding Investment in a
Potential Co-Investment Transaction and the Regulated Funds and
Affiliated Funds have not previously participated in a Co-Investment
Transaction with respect to the issuer:
    (i). The Adviser to such Regulated Fund or Affiliated Fund will
notify each Regulated Fund that holds an investment in the issuer of
the proposed Disposition at the earliest practical time;
    (ii). the Adviser to each Regulated Fund that holds an investment
in the issuer will formulate a recommendation as to participation by
such Regulated Fund in the Disposition; and
    (iii). the Advisers will provide to the Board of each Regulated
Fund that holds an investment in the issuer all information relating to
the existing investments in the issuer of the Regulated Funds and
Affiliated Funds, including the terms of such investments and how they
were made, that is necessary for the Required Majority to make the
findings required by this Condition.
    (b). Enhanced Board Approval. The Adviser will provide its written
recommendation as to the Regulated Fund's participation to the Eligible
Directors, and the Regulated Fund will participate in such Disposition
solely to the extent that a Required Majority determines that:
    (i). The Disposition complies with Condition 2(c)(i), (ii),
(iii)(A), and (iv); and
    (ii). the making and holding of the Pre-Boarding Investments were
not prohibited by Rule 17d-1 and records the basis for the finding in
the Board minutes.
    (c). Additional Requirements: The Disposition may only be completed
in reliance on the Order if:
    (i). Same Terms and Conditions. Each Regulated Fund has the right
to participate in such Disposition on a proportionate basis, at the
same price and on the same terms and Conditions as those applicable to
the Affiliated Funds and any other Regulated Fund;
    (ii). Original Investments. All of the Affiliated Funds' and
Regulated Funds' investments in the issuer are Pre-Boarding
Investments;
    (iii). Advice of counsel. Independent counsel to the Board advises
that the making and holding of the investments in the Pre-Boarding
Investments were not prohibited by Rule 17d-1.
    (iv). Multiple Classes of Securities. All Regulated Funds and
Affiliated Funds that hold Pre-Boarding Investments in the issuer
immediately before the time of completion of the Co-Investment
Transaction hold the same security or securities of the issuer. For the
purpose of determining whether the Regulated Funds and Affiliated Funds
hold the same security or securities, they may disregard any security
held by some but not all of them if, prior to relying on the Order, the
Required Majority is presented with all information necessary to make a
finding, and finds, that: (x) Any Regulated Fund's or Affiliated Fund's
holding of a different class of securities (including for this purpose
a security with a different maturity date) is immaterial \26\ in
amount, including immaterial relative to the size of the issuer; and
(y) the Board records the basis for any such finding in its minutes. In
addition, securities that differ only in respect of issuance date,
currency, or denominations may be treated as the same security; and
---------------------------------------------------------------------------

    \26\ In determining whether a holding is ``immaterial'' for
purposes of the Order, the Required Majority will consider whether
the nature and extent of the interest in the transaction or
arrangement is sufficiently small that a reasonable person would not
believe that the interest affected the determination of whether to
enter into the transaction or arrangement or the terms of the
transaction or arrangement.
---------------------------------------------------------------------------

    (v). No control. The Affiliated Funds, the other Regulated Funds
and their

affiliated persons (within the meaning of Section 2(a)(3)(C) of the
Act), individually or in the aggregate, do not control the issuer of
the securities (within the meaning of Section 2(a)(9) of the Act).
    8. Standard Review Follow-Ons.
    (a). General. If any Regulated Fund or Affiliated Fund desires to
make a Follow-On Investment in an issuer and the Regulated Funds and
Affiliated Funds holding investments in the issuer previously
participated in a Co-Investment Transaction with respect to the issuer:
    (i). The Adviser to each such Regulated Fund or Affiliated Fund
will notify each Regulated Fund that holds securities of the portfolio
company of the proposed transaction at the earliest practical time; and
    (ii). the Adviser to each Regulated Fund that holds an investment
in the issuer will formulate a recommendation as to the proposed
participation, including the amount of the proposed investment, by such
Regulated Fund.
    (b). No Board Approval Required. A Regulated Fund may participate
in the Follow-On Investment without obtaining prior approval of the
Required Majority if:
    (i). (A) The proposed participation of each Regulated Fund and each
Affiliated Fund in such investment is proportionate to its outstanding
investments in the issuer or the security at issue, as appropriate,\27\
immediately preceding the Follow-On Investment; and (B) the Board of
the Regulated Fund has approved as being in the best interests of the
Regulated Fund the ability to participate in Follow-On Investments on a
pro rata basis (as described in greater detail in the application); or
---------------------------------------------------------------------------

    \27\ To the extent that a Follow-On Investment opportunity is in
a security or arises in respect of a security held by the
participating Regulated Funds and Affiliated Funds, proportionality
will be measured by each participating Regulated Fund's and
Affiliated Fund's outstanding investment in the security in question
immediately preceding the Follow-On Investment using the most recent
available valuation thereof. To the extent that a Follow-On
Investment opportunity relates to an opportunity to invest in a
security that is not in respect of any security held by any of the
participating Regulated Funds or Affiliated Funds, proportionality
will be measured by each participating Regulated Fund's and
Affiliated Fund's outstanding investment in the issuer immediately
preceding the Follow-On Investment using the most recent available
valuation thereof.
---------------------------------------------------------------------------

    (ii). it is a Non-Negotiated Follow-On Investment.
    (c). Standard Board Approval. In all other cases, the Adviser will
provide its written recommendation as to the Regulated Fund's
participation to the Eligible Directors and the Regulated Fund will
participate in such Follow-On Investment solely to the extent that a
Required Majority makes the determinations set forth in Condition 2(c).
If the only previous Co-Investment Transaction with respect to the
issuer was an Enhanced Review Disposition the Eligible Directors must
complete this review of the proposed Follow-On Investment both on a
stand-alone basis and together with the Pre-Boarding Investments in
relation to the total economic exposure and other terms of the
investment.
    (d). Allocation. If, with respect to any such Follow-On Investment:
    (i). The amount of the opportunity proposed to be made available to
any Regulated Fund is not based on the Regulated Funds' and the
Affiliated Funds' outstanding investments in the issuer or the security
at issue, as appropriate, immediately preceding the Follow-On
Investment; and
    (ii). the aggregate amount recommended by the Advisers to be
invested in the Follow-On Investment by the participating Regulated
Funds and any participating Affiliated Funds, collectively, exceeds the
amount of the investment opportunity, then the Follow-On Investment
opportunity will be allocated among them pro rata based on the size of
the Internal Orders, as described in section III.A.1.b. of the
application.
    (e). Other Conditions. The acquisition of Follow-On Investments as
permitted by this Condition will be considered a Co-Investment
Transaction for all purposes and subject to the other Conditions set
forth in the application.
    9. Enhanced Review Follow-Ons.
    (a). General. If any Regulated Fund or Affiliated Fund desires to
make a Follow-On Investment in an issuer that is a Potential Co-
Investment Transaction and the Regulated Funds and Affiliated Funds
holding investments in the issuer have not previously participated in a
Co-Investment Transaction with respect to the issuer:
    (i). The Adviser to each such Regulated Fund or Affiliated Fund
will notify each Regulated Fund that holds securities of the portfolio
company of the proposed transaction at the earliest practical time;
    (ii). the Adviser to each Regulated Fund that holds an investment
in the issuer will formulate a recommendation as to the proposed
participation, including the amount of the proposed investment, by such
Regulated Fund; and
    (iii). the Advisers will provide to the Board of each Regulated
Fund that holds an investment in the issuer all information relating to
the existing investments in the issuer of the Regulated Funds and
Affiliated Funds, including the terms of such investments and how they
were made, that is necessary for the Required Majority to make the
findings required by this Condition.
    (b). Enhanced Board Approval. The Adviser will provide its written
recommendation as to the Regulated Fund's participation to the Eligible
Directors, and the Regulated Fund will participate in such Follow-On
Investment solely to the extent that a Required Majority reviews the
proposed Follow-On Investment both on a stand-alone basis and together
with the Pre-Boarding Investments in relation to the total economic
exposure and other terms and makes the determinations set forth in
Condition 2(c). In addition, the Follow-On Investment may only be
completed in reliance on the Order if the Required Majority of each
participating Regulated Fund determines that the making and holding of
the Pre-Boarding Investments were not prohibited by Rule 17d-1. The
basis for the Board's findings will be recorded in its minutes.
    (c). Additional Requirements. The Follow-On Investment may only be
completed in reliance on the Order if:
    (i). Original Investments. All of the Affiliated Funds' and
Regulated Funds' investments in the issuer are Pre-Boarding
Investments;
    (ii). Advice of counsel. Independent counsel to the Board advises
that the making and holding of the investments in the Pre-Boarding
Investments were not prohibited by Rule 17d-1;
    (iii). Multiple Classes of Securities. All Regulated Funds and
Affiliated Funds that hold Pre-Boarding Investments in the issuer
immediately before the time of completion of the Co-Investment
Transaction hold the same security or securities of the issuer. For the
purpose of determining whether the Regulated Funds and Affiliated Funds
hold the same security or securities, they may disregard any security
held by some but not all of them if, prior to relying on the Order, the
Required Majority is presented with all information necessary to make a
finding, and finds, that: (x) Any Regulated Fund's or Affiliated Fund's
holding of a different class of securities (including for this purpose
a security with a different maturity date) is immaterial in amount,
including immaterial relative to the size of the issuer; and (y) the
Board records the basis for any such finding in its minutes. In
addition, securities that differ only in respect of issuance date,

currency, or denominations may be treated as the same security; and
    (iv). No control. The Affiliated Funds, the other Regulated Funds
and their affiliated persons (within the meaning of Section 2(a)(3)(C)
of the Act), individually or in the aggregate, do not control the
issuer of the securities (within the meaning of Section 2(a)(9) of the
Act).
    (d). Allocation. If, with respect to any such Follow-On Investment:
    (i). The amount of the opportunity proposed to be made available to
any Regulated Fund is not based on the Regulated Funds' and the
Affiliated Funds' outstanding investments in the issuer or the security
at issue, as appropriate, immediately preceding the Follow-On
Investment; and
    (ii). the aggregate amount recommended by the Advisers to be
invested in the Follow-On Investment by the participating Regulated
Funds and any participating Affiliated Funds, collectively, exceeds the
amount of the investment opportunity, then the Follow-On Investment
opportunity will be allocated among them pro rata based on the size of
the Internal Orders, as described in section III.A.1.b. of the
application.
    (e). Other Conditions. The acquisition of Follow-On Investments as
permitted by this Condition will be considered a Co-Investment
Transaction for all purposes and subject to the other Conditions set
forth in the application.
    10. Board Reporting, Compliance and Annual Re-Approval.
    (a). Each Adviser to a Regulated Fund will present to the Board of
each Regulated Fund, on a quarterly basis, and at such other times as
the Board may request, (i) a record of all investments in Potential Co-
Investment Transactions made by any of the other Regulated Funds or any
of the Affiliated Funds during the preceding quarter that fell within
the Regulated Fund's then-current Objectives and Strategies and Board-
Established Criteria that were not made available to the Regulated
Fund, and an explanation of why such investment opportunities were not
made available to the Regulated Fund; (ii) a record of all Follow-On
Investments in and Dispositions of investments in any issuer in which
the Regulated Fund holds any investments by any Affiliated Fund or
other Regulated Fund during the prior quarter; and (iii) all
information concerning Potential Co-Investment Transactions and Co-
Investment Transactions, including investments made by other Regulated
Funds or Affiliated Funds that the Regulated Fund considered but
declined to participate in, so that the Independent Directors, may
determine whether all Potential Co-Investment Transactions and Co-
Investment Transactions during the preceding quarter, including those
investments that the Regulated Fund considered but declined to
participate in, comply with the Conditions.
    (b). All information presented to the Regulated Fund's Board
pursuant to this Condition will be kept for the life of the Regulated
Fund and at least two years thereafter, and will be subject to
examination by the Commission and its staff.
    (c). Each Regulated Fund's chief compliance officer, as defined in
rule 38a-1(a)(4), will prepare an annual report for its Board each year
that evaluates (and documents the basis of that evaluation) the
Regulated Fund's compliance with the terms and Conditions of the
application and the procedures established to achieve such compliance.
    (d). The Independent Directors will consider at least annually
whether continued participation in new and existing Co-Investment
Transactions is in the Regulated Fund's best interests.
    11. Record Keeping. Each Regulated Fund will maintain the records
required by Section 57(f)(3) of the Act as if each of the Regulated
Funds were a BDC and each of the investments permitted under these
Conditions were approved by the Required Majority under Section 57(f).
    12. Director Independence. No Independent Director of a Regulated
Fund will also be a director, general partner, managing member or
principal, or otherwise be an ``affiliated person'' (as defined in the
Act) of any Affiliated Fund.
    13. Expenses. The expenses, if any, associated with acquiring,
holding or disposing of any securities acquired in a Co-Investment
Transaction (including, without limitation, the expenses of the
distribution of any such securities registered for sale under the
Securities Act) will, to the extent not payable by the Advisers under
their respective advisory agreements with the Regulated Funds and the
Affiliated Funds, be shared by the Regulated Funds and the
participating Affiliated Funds in proportion to the relative amounts of
the securities held or being acquired or disposed of, as the case may
be.
    14. Transaction Fees.\28\ Any transaction fee (including break-up,
structuring, monitoring or commitment fees but excluding brokerage or
underwriting compensation permitted by Section 17(e) received in
connection with any Co-Investment Transaction will be distributed to
the participants on a pro rata basis based on the amounts they invested
or committed, as the case may be, in such Co-Investment Transaction. If
any transaction fee is to be held by an Adviser pending consummation of
the transaction, the fee will be deposited into an account maintained
by an Adviser at a bank or banks having the qualifications prescribed
in Section 26(a)(1), and the account will earn a competitive rate of
interest that will also be divided pro rata among the participants.
None of the Adviser, the Affiliated Funds, the other Regulated Funds or
any affiliated person of the Affiliated Funds or the Regulated Funds
will receive any additional compensation or remuneration of any kind as
a result of or in connection with a Co-Investment Transaction other
than (i) in the case of the Regulated Funds and the Affiliated Funds,
the pro rata transaction fees described above and fees or other
compensation described in Condition 2(c)(iii)(B)(z), (ii) brokerage or
underwriting compensation permitted by Section 17(e) or (iii) in the
case of the Adviser, investment advisory compensation paid in
accordance with investment advisory agreements between the applicable
Regulated Fund(s) or Affiliated Fund(s) and its Adviser.
---------------------------------------------------------------------------

    \28\ Applicants are not requesting and the Commission is not
providing any relief for transaction fees received in connection
with any Co-Investment Transaction.
---------------------------------------------------------------------------

    15. Independence. If the Holders own in the aggregate more than 25
percent of the Shares of a Regulated Fund, then the Holders will vote
such Shares as directed by an independent third party when voting on
(1) the election of directors; (2) the removal of one or more
directors; or (3) any other matter under either the Act or applicable
State law affecting the Board's composition, size or manner of
election.

    For the Commission, by the Division of Investment Management,
under delegated authority.
J. Matthew DeLesDernier,
Assistant Secretary.
[FR Doc. 2019-28491 Filed 1-3-20; 8:45 am]
 BILLING CODE 8011-01-P